Search results
We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines. We are committed to developing novel therapies for respiratory diseases with significant unmet medical needs, such as COPD, non-cystic fibrosis bronchiectasis, cystic fibrosis and asthma.
Sep 11, 2023 · LONDON and RALEIGH, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) has...
3 days ago · Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
Sep 11, 2023 · LONDON and RALEIGH, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) has...
2 days ago · Verona Pharma plc: US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200: Victoria Stewart, Senior Director of Investor Relations and Communications
LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care Medicine (“AJRCCM”) has published results from its Phase 3 ENHANCE trials evaluating ensifentrine in chronic obstructive pulmonary disease (“COPD”).
